Johnson & Johnson’s stock rose 1.5% in premarket trade Tuesday, after the medtech and drug company posted better-than-expected third-quarter earnings and raised its profit guidance.
Sales rose 6.8% to $21.351 billion from $19.996 billion a year ago, also ahead of the $21.036 billion FactSet consensus. The company spun off its consumer health business earlier this year into a separate company called Kenvue KVUE, +0.88%. Kenvue houses the company’ consumer health business which includes a host of household name brands, including Tylenol, Listerine, Band-Aid, Neutrogena and Nicorette.
It expects full-year EPS to range from $10.02 to $10.08, compared with prior guidance of $9.90 to $10.00. The company expects adjusted EPS to range from $10.07 to $10.13, compared with prior guidance of $10.00 to $10.10.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Lire la suite »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Lire la suite »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Lire la suite »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Lire la suite »
Earnings: Early Trend Suggests EPS Growth May Have Already Bottomed in Fiscal Q2Market Overview Analysis by Investing.com (Francesco Casarella) covering: S&P 500, iShares Core S&P 500 ETF, SPDR® S&P 500, S&P 500 Futures. Read Investing.com (Francesco Casarella)'s latest article on Investing.com
Lire la suite »